Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 267 shares, a decrease of 93.5% from the August 31st total of 4,133 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 53,604 shares, the days-to-cover ratio is presently 0.0 days.

Addex Therapeutics Price Performance

Shares of NASDAQ:ADXN opened at $3.46 on Friday. The firm has a fifty day moving average price of $4.67 and a two-hundred day moving average price of $5.85. The company has a market cap of $4.26 million, a price-to-earnings ratio of -0.58 and a beta of 1.47. Addex Therapeutics has a one year low of $3.10 and a one year high of $11.97.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company develops small-molecule medicines that act through allosteric modulation, a drug-discovery approach designed to influence G protein-coupled receptors (GPCRs) at sites distinct from where naturally occurring signaling molecules bind.

Addex’s research has focused primarily on treatments for disorders of the central nervous system. Its development programs have included ADX71149, an investigational positive allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), and other compounds targeting neurological and psychiatric conditions.